With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Vision loss due to Glaucoma can be prevented if it is detected and treated early
The validations confirm the completion of the applications and commence the scientific review process
Acquisition of exclusive commercialization rights for European markets
This agreement paves the way for the introduction of YESAFILI into the Canadian market
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
BHL will undertake the development and supply of these molecules
Subscribe To Our Newsletter & Stay Updated
